Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
TELESCOPE INNOVATIONS CP (TELIF) is a leading developer of chemical technologies for the pharmaceutical and chemical industries. The company specializes in scalable manufacturing processes and tools, including flexible robotic platforms and artificial intelligence software. With a focus on process innovation, TELIF aims to address challenges in health and sustainability by improving experimental throughput, efficiency, and data quality. Recent achievements include the development of a proprietary recrystallization process for battery recycling feeds and partnerships with industry leaders like METTLER TOLEDO and Shimadzu Scientific Instruments.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has signed a master collaborative research agreement with Pfizer Inc. to develop technology aimed at accelerating pharmaceutical R&D through automation, robotics, and artificial intelligence. The multi-year agreement focuses on deploying Self-Driving Laboratories (SDLs), which can optimize material properties and chemical synthesis methods up to 100x faster than traditional research methods.
The collaboration builds on Telescope's previous success in commercializing its DirectInject-LC™ automation product for online chemistry analysis. A joint steering committee will guide the technology development projects, ensuring Telescope's SDL technology is well-positioned for the pharmaceutical industry. This partnership could significantly reduce the time and cost of developing new pharmaceuticals, potentially providing a key competitive advantage in the industry.
Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) has been awarded $400,273 in early-stage funding from the B.C. Centre for Innovation and Clean Energy (CICE) to pilot its proprietary Recrystallization Refinement Technology (ReCRFT™). This technology is a carbon-negative and low-cost method to produce battery-grade lithium carbonate from saltwater brines.
ReCRFT is inspired by pharmaceutical manufacturing approaches and offers advantages such as continuous operation, high process yield, high impurity tolerance, and reduced reagent utilization. It is estimated to reduce lithium refinery plant CapEx by 15-25% and OpEx by 25% compared to incumbent technologies.
The funding will support Telescope's lab-scale pilot, providing key engineering studies and continuous operation demonstrations for potential licensing customers. This project builds on Telescope's previous research efforts with Standard Lithium, Natural Resources Canada, and Canada's Mining Innovation Commercialization Accelerator.
Telescope Innovations, a developer of advanced technologies for the pharmaceutical and chemical industries, announced financial results for Q3 FY 2024. The company reported revenues of CAD $1.2 million for the quarter, with year-to-date revenues exceeding CAD $3.4 million, surpassing the entire fiscal year 2023's revenues. Despite the revenue increase, expenses also rose to CAD $1.42 million for the quarter and CAD $3.94 million year-to-date. However, the company achieved a positive cash flow from operating activities of CAD $40,023 for the year-to-date period. This quarter saw increased sales of the DirectInject-LC product and notable customer engagement through conferences and technology demonstrations.
Telescope Innovations Corp. (CSE: TELI, OTCQB: TELIF), a developer of advanced pharmaceutical and chemical technologies, has joined the MaRS Discovery District, North America's largest urban innovation hub. MaRS supports member companies with advisory services, access to capital and talent, events, and workspace. MaRS companies have raised over CAD $19 billion in investments since 2010, with revenues surpassing CAD $11.5 billion.
Telescope's acceptance into MaRS comes as it advances the commercial deployment of its lithium refinement technology, ReCRFT™, which simplifies the production of battery-grade lithium carbonate from various sources, reducing manufacturing costs. The company aims to support the global transition to clean energy by addressing the growing demand for battery raw materials.
Telescope Innovations Corp. (CSE: TELI, OTCQB: TELIF) will participate in the 2024 Lithium Supply and Battery Raw Materials Conference in Las Vegas from June 24-27.
Dr. Ryan Jansonius and Jeffrey Sherman will present their proprietary lithium refinement technology, ReCRFT™, which produces battery-quality lithium carbonate from brines in a single step, reducing manufacturing costs and eliminating the need for additional feed polishing steps.
The technology is compatible with impure and variable feedstocks and has garnered significant industry attention. A detailed white paper is available on Telescope's website.
The conference provides a platform for Telescope to engage with industry stakeholders and promote the industrial adoption and commercial deployment of their technology.
Telescope Innovations Corp. will showcase its DirectInject-LC™ product and process IP at METTLER TOLEDO events, highlighting innovations in synthetic chemistry and process manufacturing. The company's participation in the New Jersey and Montreal InfoDays will feature their flagship product for online chemistry sampling and analysis, as well as their cutting-edge lithium refinement technology for battery materials. These events enhance industry networking, promote automation and analytical technologies, and underscore Telescope's commitment to innovation and strategic growth.
FAQ
What is the current stock price of TELESCOPE INNOVATIONS (TELIF)?
What is the market cap of TELESCOPE INNOVATIONS (TELIF)?
What are the core business operations of TELESCOPE INNOVATIONS CP (TELIF)?
What recent achievements has TELESCOPE INNOVATIONS CP (TELIF) made?
What is the focus of TELESCOPE INNOVATIONS CP (TELIF)'s technology?
Who are some of TELESCOPE INNOVATIONS CP (TELIF)'s key partners?
